Company performance
Current Price
as of Jan 17, 2025$5.91
P/E Ratio
N/A
Market Cap
$1.8B
Description
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Metrics
Overview
- HQSan Carlos, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerIOVA
- Price$5.91+2.60%
Trading Information
- Market cap$1.80B
- Float81.06%
- Average Daily Volume (1m)9,213,057
- Average Daily Volume (3m)7,576,859
- EPS-$1.50
Company
- Revenue$90.86M
- Rev growth (1yr)12,385.07%
- Net income-$83.54M
- Gross margin22.41%
- EBITDA margin-133.07%
- EBITDA-$77.92M
- EV$2.53B
- EV/Revenue27.84
- P/EN/A
- P/S19.73
- P/B2.33
Documents
SEC Filings
Earnings Calls